So, the federal government shut down while America slept, but it reopened after a five-and-a-half hour pause, by early morning Feb. 9. We’ve seen this dance before.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
